Sagimet Biosciences (SGMT) Preferred Stock Liabilities (2022 - 2023)
Sagimet Biosciences' (SGMT) quarterly Preferred Stock Liabilities came in at $214.6 million in Q2 2023, little changed year-on-year from $214.6 million in Q2 2022, and little changed quarter-over-quarter from $214.6 million in Q1 2023.
Sagimet Biosciences (SGMT) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends
Sagimet Biosciences' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $214.6 million for Q2 2023.
- On a quarterly basis, Preferred Stock Liabilities changed 0.0% year-over-year to $214.6 million in Q2 2023; TTM through Jun 2023 was $214.6 million, a 0.0% change from a year earlier, with the FY2022 full-year figure at $214.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities held at $214.6 million in Q2 2023 per SGMT's latest filing, from $214.6 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $214.6 million in Q2 2022 and bottomed at $214.6 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Sagimet Biosciences | 228.24 Mn | 228.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 214.62 Mn |
| Mar 31, 2023 | 214.62 Mn |
| Dec 31, 2022 | 214.62 Mn |
| Sep 30, 2022 | 214.62 Mn |
| Jun 30, 2022 | 214.62 Mn |